SUCROSOMIAL TECHNOLOGY

A unique delivery system, a revolution in the field of nutraceuticals, which guarantees maximum efficacy in transporting and absorbing essential bioactive compounds.

CETYLATED FATTY ACIDS

A patented solution designed to enhance joint and muscle mobility, known for its exceptional skin penetration and rapid absorption.

PRODUCTS

PharmaNutra products are designed to provide a safe and effective response to health and well-being requirements at any stage of life.
R&D

We are committed to advancing nutraceutical science by developing effective, high-quality supplements and medical devices.

In our laboratories, we use cutting-edge research models to drive innovation, blending solid scientific methods with a forward-thinking approach to technology and patents. PharmaNutra's research focuses on key health areas, especially addressing nutritional deficiencies in minerals and vitamins, supporting muscle and joint health and enhancing functional and sports nutrition.

MORE
THERAPEUTIC AREAS

Our scientific research

NEWS

Inform, innovate, inspire: putting health first

Stay updated with the latest from PharmaNutra: scientific insights, events, groundbreaking products and updates tailored to support your professional practice.
News & Events

SiderAL® racing in Miami with the M32 catamaran

Read more
News & Events

PharmaNutra takes part int the Aim Italia Conference 2020

Read more
Intranet

PharmaNutra to sponsor the Giro d’Italia for the three-year period 2025-2027

Read more
News & Events

Cetilar Villorba Corse at the start of the 24 Hours of Le Mans 2018

Read more
Iron deficiency

Sucrosomial® Iron: new clinical trial performed by Dr. Guillermo Bastida

Read more
Iron deficiency

New scientific studies on Sucrosomial® Technology applied to iron

Read more
Iron deficiency

Iron deficiency in IBD, celiac disease and obesity

Read more
Raw materials

Ultrazin®, Ultrachrome®, Ultraiod®, Ultrasel®: focus on Sucrosomial® micro-elements

Read more
Iron deficiency

PharmaNutra at the NATA Symposium 2019 for the third consecutive year

Read more
Senza categoria

PharmaNutra obtains patent for a new composition for treating cardiovascular diseases

Read more
News & Events

Cetilar Run 2018: 1700 runners for a record edition

Read more
Raw materials

Alesco-PharmaNutra Merger: from July 2024, Alesco will become a business division of the Group

Read more
News & Events

World Partners Convention 2018: a borderless success

Read more
Iron deficiency

Sucrosomial Iron quoted in Expert Opinion on Pharmacotherapy

Read more
News & Events

Third ACT of the Cetilar M32 European Sailing Series

Read more